Agios Pharmaceuticals financials
$33.30−0.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.7M | $20.7M | $20.0M | $12.9M | $12.5M | $8.7M | $10.7M | $9.0M | $8.6M | $8.2M | $7.1M | $7.4M |
| Gross profit | $41.7M | $19.4M | $18.1M | $11.2M | $10.8M | $7.6M | $9.5M | $8.2M | $7.1M | $7.6M | $6.5M | $6.8M |
| Gross margin | 93.3% | 93.6% | 90.6% | 87.0% | 86.3% | 87.6% | 88.3% | 91.3% | 82.6% | 92.3% | 91.8% | 91.4% |
| Operating income | -$110.6M | -$110.0M | -$121.6M | -$116.9M | -$127.1M | -$106.6M | -$125.0M | -$102.8M | -$105.8M | -$92.1M | -$106.3M | -$100.9M |
| Net income | -$100.7M | -$99.1M | -$108.0M | -$103.4M | -$112.0M | -$89.3M | -$96.5M | $947.9M | -$96.1M | -$81.5M | -$95.9M | -$91.3M |
| Net margin | −225.1% | −477.7% | −541.1% | −803.1% | −899.4% | −1023.3% | −899.6% | 10574.7% | −1115.7% | −995.8% | −1350.7% | −1234.3% |
| Diluted EPS | $-1.69 | $-1.69 | $-1.85 | $-1.78 | $-1.93 | $-1.55 | $-1.61 | $16.22 | $-1.69 | $-1.45 | $-1.72 | $-1.64 |
| EBITDA | -$109.2M | -$108.7M | -$120.3M | -$115.5M | -$125.8M | -$105.4M | -$123.7M | -$101.4M | -$104.3M | -$90.7M | -$106.3M | -$99.3M |
| Operating cash flow | -$57.3M | -$118.9M | -$96.2M | -$88.2M | -$77.1M | -$111.5M | -$133.2M | -$84.2M | -$72.6M | -$99.9M | -$72.5M | -$61.6M |
| Free cash flow | -$58.5M | -$119.7M | -$97.3M | -$89.7M | -$78.0M | -$112.3M | -$134.1M | -$84.6M | -$72.7M | -$100.0M | -$72.7M | -$62.0M |
| Diluted shares | 59.5M | 58.8M | 58.4M | 58.1M | 57.9M | 57.5M | 59.9M | 58.4M | 56.8M | 56.4M | 55.9M | 55.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $99.6M | $113.6M | $89.1M | $92.7M | $80.9M | $79.0M |
| Short-term investments | $517.9M | $623.4M | $765.3M | $860.1M | $858.1M | $814.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B |
| Total liabilities | $82.4M | $75.9M | $104.1M | $101.4M | $101.7M | $89.0M |
| Shareholders' equity | $1.03B | $1.11B | $1.19B | $1.28B | $1.37B | $1.47B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology